Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Mendelics | RCV000120862 | SCV002517031 | uncertain significance | not specified | 2022-05-04 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002483214 | SCV002790720 | uncertain significance | Xeroderma pigmentosum, group G; Cerebrooculofacioskeletal syndrome 3 | 2022-02-08 | criteria provided, single submitter | clinical testing | |
Invitae | RCV002514633 | SCV003267045 | uncertain significance | not provided | 2022-06-14 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The leucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. ClinVar contains an entry for this variant (Variation ID: 134189). This variant has not been reported in the literature in individuals affected with ERCC5-related conditions. This variant is present in population databases (rs201684551, gnomAD 0.07%). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 524 of the ERCC5 protein (p.Pro524Leu). |
Revvity Omics, |
RCV002514633 | SCV003833582 | uncertain significance | not provided | 2020-04-03 | criteria provided, single submitter | clinical testing | |
ITMI | RCV000120862 | SCV000085029 | not provided | not specified | 2013-09-19 | no assertion provided | reference population |